# E-DRUG: Appropriate Marketing of Pharmaceutics

**URL:** <https://talk.edrugplus.org/t/e-drug-appropriate-marketing-of-pharmaceutics/2334>\
**Category:** e-drug\
**Created:** [March 23, 1998, 7:52pm UTC](https://talk.edrugplus.org/t/e-drug-appropriate-marketing-of-pharmaceutics/2334 "1998-03-23T19:52:41Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![Bagdadi](https://avatars.discourse-cdn.com/v4/letter/b/aca169/32.png) [@Bagdadi](https://talk.edrugplus.org/u/Bagdadi)\
**Post date:** [March 23, 1998, 7:52pm UTC](https://talk.edrugplus.org/t/e-drug-appropriate-marketing-of-pharmaceutics/2334/1 "1998-03-23T19:52:41Z")

</div>

E-drug: Appropriate Marketing of Pharmaceutics  
---------------------------------------------

Dear E-Druggers,

As a student of the Health Sciences (La Trobe University, Melbourne-  
Australia), Pharmacology and the issues surrounding the industry are  
of some interest to me. I am currently undertaking an Honors project  
based on the appropriate marketing of pharmaceutics, particularly with  
respect to the marketing techniques employed by the industries sales  
representatives.

Previous research (including a study based at La Trobe University by  
Libby Roughead) examined the interaction between the representative  
and the general practitioner. Findings highlighted the fact that  
although the representative provided information on indications, dosage  
and administration, information associated with product risk was  
minimal. The information supplied to the general practitioner was  
occasionally inaccurate and was found to promote product benefits  
while downplaying risks.

However, research which investigates the interaction between the  
general practitioner and the representative alone, does not suffice in  
revealing the origin of these behaviors and techniques. It is postulated  
that industry and company self-regulatory culture, training, super-  
vision and internal quality control procedures are key influences on  
representative behavior. In recent years efforts by the pharmaceutical  
industry in Australia have led to substantial advances in this area.  
Despite this, there does not seem to be any available in the public  
domain. My research aims to document industry efforts concerning the  
self-regulation of pharmaceutical representatives.

My purpose in writing is to  
1. request any information subscribers may have on this issue,  
2. listen to any helpful ideas, or  
3. partake in discussions/controversies

Any information forwarded would be much appreciated.

Deran Bagdadi  
School of Public Health, La Trobe University  
Melbourne, Australia  
e-mail: dadi@i.net.au

Note: A full proposal as well as a list of references will hopefully be  
posted on the web within the next few weeks. I'll keep subscribers  
updated.  
--  
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.  
Mail administrative requests to `majordomo@usa.healthnet.org'.  
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.